Takeda Pharmaceutical Company Limited (TAK) – Strong Start to the Fiscal Year

Takeda Pharmaceutical Company Limited (TAK) (Q1FY23)

Stock Performance – Takeda stock price showed a volatile trend in the past 3 months. It declined by 2.75% during the period. The stock price increased by 14.9% in past 1-year. The stock has a 52-week high of $4873 and its 52-week low is $3708.

In the past 3 years, the stock has given returns of 21.07%. TAK has a 50-day moving Avg. and 200-day moving Avg. of $4525 and $4398, respectively.

Revenue Performance – TAK Revenue was JPY 1,058.6bn (JPY +86.2bn and +8.9% AER, +3.7% CER) in Q1FY23. The increase is primarily attributable to favorable foreign exchange rates and growth from the business momentum of five key business areas, with the exception of Oncology which was impacted by generic erosion and intensified competition on certain products in the current period.

Company Guidance for FY23 – TAK expects Core Revenue Low-single-digit % decline. Core Operating Profit low-10s % decline, Core EPS of low-20s % decline.

Highlights

QDENGA is finding success in both the endemic market (the market in which it primarily operates) and the travel market. This implies that the product or service is applicable and in demand in a variety of contexts, which can be advantageous for business diversification and stability.

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– PE Band Comparison
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10-Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 34

To download the previous quarter’s equity/report CLICK HERE

To Download other equity/reports CLICK HERE

Follow our LinkedIn page for more updates.